BR112019000049A2 - terapias combinadas para o tratamento do câncer - Google Patents
terapias combinadas para o tratamento do câncerInfo
- Publication number
- BR112019000049A2 BR112019000049A2 BR112019000049-6A BR112019000049A BR112019000049A2 BR 112019000049 A2 BR112019000049 A2 BR 112019000049A2 BR 112019000049 A BR112019000049 A BR 112019000049A BR 112019000049 A2 BR112019000049 A2 BR 112019000049A2
- Authority
- BR
- Brazil
- Prior art keywords
- inv
- therapeutically effective
- effective combination
- cancer treatment
- pharmaceutically acceptable
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
esta invenção refere-se a métodos e composições para o tratamento da leucemia com inv(16) e, particularmente, para o tratamento da leucemia mieloide aguda. é descrito um método para o tratamento da leucemia com inv(16), o qual compreende a etapa de administrar, a um indivíduo que necessita do mesmo, uma combinação terapeuticamente eficaz de a) um composto da fórmula (1) (1) e b) um agente quimioterápico selecionado do grupo que consiste em pirarrubicina, aclarrubicina, mitoxantrona, doxorrubicina, daunorrubicina, idarrubicina, epirrubicina, citarabina, sais farmaceuticamente aceitáveis e misturas dos mesmos. a combinação terapeuticamente eficaz inibe sinergicamente a proliferação de células leucêmicas com inv(16). esta invenção também se refere a composições farmacêuticas compreendendo uma combinação terapeuticamente eficaz do composto de fórmula (1) e o agente quimioterápico e um excipiente farmaceuticamente aceitável.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662367263P | 2016-07-27 | 2016-07-27 | |
| US62/367.263 | 2016-07-27 | ||
| PCT/US2017/044124 WO2018022855A1 (en) | 2016-07-27 | 2017-07-27 | Combination therapies for treating cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112019000049A2 true BR112019000049A2 (pt) | 2019-04-02 |
Family
ID=61016782
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112019000049-6A BR112019000049A2 (pt) | 2016-07-27 | 2017-07-27 | terapias combinadas para o tratamento do câncer |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US11241421B2 (pt) |
| EP (1) | EP3490557B1 (pt) |
| JP (1) | JP2019525924A (pt) |
| KR (1) | KR20190032370A (pt) |
| CN (1) | CN109475542A (pt) |
| AU (1) | AU2017302330A1 (pt) |
| BR (1) | BR112019000049A2 (pt) |
| CA (1) | CA3028461A1 (pt) |
| EA (1) | EA201990395A1 (pt) |
| IL (1) | IL263942A (pt) |
| MX (1) | MX2019000179A (pt) |
| WO (1) | WO2018022855A1 (pt) |
| ZA (1) | ZA201900438B (pt) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019226975A1 (en) * | 2018-05-24 | 2019-11-28 | University Of Virginia Patent Foundation | Combination therapies for treating cancer |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5643935A (en) * | 1995-06-07 | 1997-07-01 | The University Of North Carolina At Chapel Hill | Method of combatting infectious diseases using dicationic bis-benzimidazoles |
| US6372719B1 (en) * | 1998-03-04 | 2002-04-16 | Jay Cunningham | ανβ3 integrin antagonists in combination with chemotherapeutic agents |
| WO2006104668A2 (en) * | 2005-03-11 | 2006-10-05 | Temple University - Of The Commonwealth System Of Higher Education | Composition and methods for the treatment of proliferative diseases |
| EP1898916A4 (en) * | 2005-07-06 | 2008-10-15 | Kanisa Pharmaceuticals Inc | ZOSUQUIDAR, DAUNORUBICIN AND CYTARABINE FOR THE TREATMENT OF CANCER |
| WO2010132684A2 (en) * | 2009-05-13 | 2010-11-18 | University Of Virginia Patent Foundation | Inhibitors of inv(16) leukemia |
-
2017
- 2017-07-27 JP JP2019503517A patent/JP2019525924A/ja active Pending
- 2017-07-27 MX MX2019000179A patent/MX2019000179A/es unknown
- 2017-07-27 US US16/318,041 patent/US11241421B2/en active Active
- 2017-07-27 AU AU2017302330A patent/AU2017302330A1/en not_active Abandoned
- 2017-07-27 EA EA201990395A patent/EA201990395A1/ru unknown
- 2017-07-27 CN CN201780045352.0A patent/CN109475542A/zh active Pending
- 2017-07-27 CA CA3028461A patent/CA3028461A1/en not_active Abandoned
- 2017-07-27 EP EP17835254.8A patent/EP3490557B1/en active Active
- 2017-07-27 BR BR112019000049-6A patent/BR112019000049A2/pt not_active IP Right Cessation
- 2017-07-27 KR KR1020197001728A patent/KR20190032370A/ko not_active Application Discontinuation
- 2017-07-27 WO PCT/US2017/044124 patent/WO2018022855A1/en unknown
-
2018
- 2018-12-24 IL IL263942A patent/IL263942A/en unknown
-
2019
- 2019-01-22 ZA ZA201900438A patent/ZA201900438B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MX2019000179A (es) | 2019-06-20 |
| EP3490557A1 (en) | 2019-06-05 |
| ZA201900438B (en) | 2019-10-30 |
| AU2017302330A1 (en) | 2019-01-17 |
| EP3490557B1 (en) | 2022-09-07 |
| WO2018022855A1 (en) | 2018-02-01 |
| US11241421B2 (en) | 2022-02-08 |
| US20190343820A1 (en) | 2019-11-14 |
| KR20190032370A (ko) | 2019-03-27 |
| JP2019525924A (ja) | 2019-09-12 |
| CN109475542A (zh) | 2019-03-15 |
| IL263942A (en) | 2019-02-28 |
| CA3028461A1 (en) | 2018-02-01 |
| EA201990395A1 (ru) | 2019-07-31 |
| EP3490557A4 (en) | 2020-04-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112022008535A2 (pt) | Composto, composição farmacêutica, métodos para tratar câncer e um distúrbio relativo à proteína ras | |
| BR112022008565A2 (pt) | Composto, composição farmacêutica, conjugado, métodos para tratar câncer e um distúrbio relativo à proteína ras | |
| BR112022008534A2 (pt) | Compostos, composição farmacêutica, conjugado e métodos para tratar câncer e para tratar um distúrbio relacionado à proteína ras | |
| AR107871A1 (es) | Combinaciones de inhibidores de lsd1 para su uso en el tratamiento de tumores sólidos | |
| BR112016028641A2 (pt) | ?método para tratar câncer? | |
| BR112022003490A2 (pt) | Método de tratamento do câncer de mama e mama metastático, método para degradação seletiva, método para inibir uma quinase, kit, composição líquida, e, método de produção de uma composição líquida | |
| BR112021021284A2 (pt) | Composto, composição farmacêutica, e, métodos para o tratamento ou profilaxia de doenças inflamatórias da pele, doenças respiratórias, doenças gastrointestinais, doenças oculares, cânceres, doenças reumáticas, doenças desmielinizantes e doenças fibróticas e de inibição da atividade de proteínas de bromodomínio e domínio terminal extra | |
| BR112021017375A2 (pt) | Composição farmacêutica combinando método imunológico e quimioterapêutico para o tratamento de câncer | |
| JP2017533222A5 (pt) | ||
| BR112023001792A2 (pt) | Combinações para o tratamento de câncer | |
| PH12020500665A1 (en) | Pladienolide derivatives as spliceosome targeting agents for treating cancer | |
| RU2018107930A (ru) | Агонисты tlr4, их композиции и применение для лечения рака | |
| MX2019003694A (es) | Metodos para tratar cancer del tracto biliar. | |
| CO2022015891A2 (es) | Administración conjunta de mirdametinib y lifirafenib para uso en el tratamiento de cánceres | |
| BR112019018615A2 (pt) | compostos antimicrobianos, composições e usos dos mesmos | |
| PH12020500666A1 (en) | Pladienolide compounds and their use | |
| NI202100031A (es) | Formulación basada en ciclodextrina de un inhibidor de bcl-2 | |
| AR096526A1 (es) | Agentes citotóxicos para el tratamiento del cáncer | |
| BR112021019187A2 (pt) | Método para repolarização de um macrófago associado a tumor de m2 a m1, e, composto para repolarização de um macrófago associado a tumor de m2 a m1 | |
| BR112019000049A2 (pt) | terapias combinadas para o tratamento do câncer | |
| BR112019008698A2 (pt) | método para tratar câncer num sujeito que precisa do mesmo e composição farmacêutica | |
| BR112022012283A2 (pt) | Combinações | |
| BR112022012284A2 (pt) | Combinações | |
| BR112019002213A2 (pt) | composições e o uso das mesmas para tratar ou prevenir rosácea | |
| PH12021550815A1 (en) | New combination solution for treating chemotherapy refractory cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] | ||
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 5A ANUIDADE. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2681 DE 24-05-2022 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |